Unlocking the potential of pyroptosis in tumor immunotherapy: a new horizon in cancer treatment DOI Creative Commons
Qinan Yin,

Si-Yuan Song,

Yuan Bian

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: June 14, 2024

Background The interaction between pyroptosis—a form of programmed cell death—and tumor immunity represents a burgeoning field interest. Pyroptosis exhibits dual role in cancer: it can both promote development and counteract by activating immune responses that inhibit evasion encourage death. Current immunotherapy strategies, notably CAR-T therapy checkpoint inhibitors (ICIs), alongside the potential certain traditional Chinese medicinal compounds, highlight intricate relationship pyroptosis cancer immunity. As research delves deeper into mechanisms within therapy, its application enhancing emerges as novel avenue. Purpose This review aims to elucidate underlying pyroptosis, impact on biology, advancements research. Methods A comprehensive literature was conducted across PubMed, Embase, CNKI, Wanfang Database from inception study until August 22, 2023. search employed keywords such “pyroptosis”, “cancer”, “tumor”, “mechanism”, “immunity”, “gasdermin”, “ICB”, “CAR-T”, “PD-1”, “PD-L1”, “herbal medicine”, “botanical “Chinese “traditional “immunotherapy”, linked AND/OR, capture latest findings immunotherapy. Results is governed complex mechanism, with Gasdermin family playing pivotal role. While promising for application, pyroptosis’s effect still evolving. Notably, medicine ingredients have been identified inducers, meriting further exploration. Conclusion consolidates current knowledge It reveals beneficial factor immunotherapeutic landscape, suggesting leveraging developing treatment including those involving medicine, forward-looking approach oncology.

Language: Английский

Self-healable and pH-responsive spermidine/ferrous ion complexed hydrogel Co-loaded with CA inhibitor and glucose oxidase for combined cancer immunotherapy through triple ferroptosis mechanism DOI
Tianqi Nie, Yifei Fang, Ruhe Zhang

et al.

Bioactive Materials, Journal Year: 2025, Volume and Issue: 47, P. 51 - 63

Published: Jan. 11, 2025

Language: Английский

Citations

2
Immune-related adverse events in older adults receiving immune checkpoint inhibitors: a comprehensive analysis of the Food and Drug Administration Adverse Event Reporting System DOI Creative Commons
Buğra Han Esen, Şevval Nur Bektaş, A. Umur Topçu

et al.

Age and Ageing, Journal Year: 2025, Volume and Issue: 54(1)

Published: Jan. 1, 2025

Abstract Background Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy, yet they carry a unique spectrum of immune-related adverse events (irAEs). Given the ageing global population and underrepresentation older adults in clinical trials for ICIs, we investigated occurrence characteristics irAEs versus younger as well among different age subsets within adult population. Methods We analysed U.S. Food Drug Administration Adverse Event Reporting System database reports from 2015 to 2023, focusing on ICIs. categorised into 11 distinct types performed descriptive multivariate analyses compare prevalence across groups, adjusting potential confounding factors. Results Among 47 513 patients aged 18–100 reporting irAEs, 65–74 75–84 groups had significantly increased risks compared 18–64 (OR 1.13, 95% CI [1.09–1.18]; 1.15 [1.1–1.21]). Cardiovascular rose with age, peaking at 75–84, while endocrine decreased. Hepatobiliary, gastrointestinal ocular decreased but renal musculoskeletal increased, showing higher adults. Serious outcomes slightly 85+ group, proportion deaths age. Conclusion discuss changes immune system contributing oldest group. Additionally, conservative treatment approaches underreporting may influence these findings. Our findings highlight need personalised decision-making ICI therapies, considering performance status comorbidities rather than alone.

Language: Английский

Citations

2
Nanoparticle-based immunoengineering strategies for enhancing cancer immunotherapy DOI

Bao-Toan Nguyen Dang,

Taeg Kyu Kwon, Sooyeun Lee

et al.

Journal of Controlled Release, Journal Year: 2023, Volume and Issue: 365, P. 773 - 800

Published: Dec. 14, 2023

Language: Английский

Citations

23
PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications DOI
Miguel Á. Ortega,

Diego Liviu Boaru,

Diego De León-Oliva

et al.

Journal of Molecular Medicine, Journal Year: 2024, Volume and Issue: 102(8), P. 987 - 1000

Published: June 27, 2024

Language: Английский

Citations

13
Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment DOI Open Access
Pankaj Kumar Garg, Siddhika Pareek, Prakash Kulkarni

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(21), P. 6537 - 6537

Published: Oct. 30, 2024

Next-generation immunotherapies have revolutionized cancer treatment, offering hope for patients with hard-to-treat tumors. This review focuses on the clinical applications and advancements of key immune-based therapies, including immune checkpoint inhibitors, CAR-T cell therapy, new vaccines designed to harness system combat malignancies. A prime example is success pembrolizumab in treatment advanced melanoma, underscoring transformative impact these therapies. Combination treatments, integrating immunotherapy chemotherapy, radiation, targeted are demonstrating synergistic benefits improving patient outcomes. also explores evolving role personalized immunotherapy, guided by biomarkers, genomic data, tumor environment, better target individual Although significant progress has been made, challenges such as resistance, side effects, high costs persist. Technological innovations, nanotechnology artificial intelligence, explored future enablers The evaluates trials, breakthroughs, emerging immune-modulating agents delivery systems that hold great promise enhancing efficacy, reducing toxicity, expanding access immunotherapy. In conclusion, this highlights ongoing reshaping care, strategies poised overcome current further extend therapeutic reach.

Language: Английский

Citations

9
Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors DOI Open Access
Ben Ponvilawan, Abdul Wali Khan, Janakiraman Subramanian

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(6), P. 1225 - 1225

Published: March 20, 2024

Immune-related adverse events (irAEs) are the most common complication of immune checkpoint inhibitor (ICI) therapy. With widespread use ICIs in patients with solid tumors, up to 40% develop irAEs within five months treatment, and 11% severe requiring interventions. A predictive test for would be a crucial tool monitoring complications during after ICI We performed an extensive review potential biomarkers who received Currently, only thyroid-stimulating hormone is utilized clinical practice. This due unavailability commercial tests unclear values from various studies. Given lack single strong biomarkers, some novel approaches using composite scores genomic, transcriptomics, cytokine levels, or parameters appear appealing. Still, these have yet validated incorporated into Further research conducted validate models before implementing them real-world settings will utmost importance irAE prediction.

Language: Английский

Citations

8
Exploring the Potential of Nanocarriers for Cancer Immunotherapy: Insights into Mechanism, Nanocarriers, and Regulatory Perspectives DOI

Tanmoy Kanp,

Anish Dhuri,

M Bharath

et al.

ACS Applied Bio Materials, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 10, 2025

Immunotherapy is a cutting-edge approach that leverages sophisticated technology to target tumor-specific antibodies and modulate the immune system eradicate cancer enhance patients' quality of life. Bioinformatics genetic science advancements have made it possible diagnose treat patients using immunotherapy technology. However, current immunotherapies against limited clinical benefits due cancer-associated antigens, which often fail interact with cells exhibit insufficient therapeutic targeting unintended side effects. To surmount this challenge, nanoparticle systems emerged as potential strategy for transporting immunotherapeutic agents activating combat tumors. Consequently, process potentially generates an antigen-specific T response effectively suppresses growth. Furthermore, nanoplatforms high specificity, efficacy, diagnostic potential, imaging capabilities, making them promising tools treatment. informative paper delves into various available immunotherapies, including CAR therapy checkpoint blockade, cytokines, vaccines, monoclonal antibodies. concept theragnostic nanotechnology, integrates diagnostics more personalized treatment therapy. Additionally, covers different nanocarrier systems, marketed products, trials, regulatory considerations, future prospects immunotherapy.

Language: Английский

Citations

1
Pembrolizumab- induced subacute cutaneous lupus erythematosus in a patient with oropharyngeal squamous cell carcinoma: A case report and literature review DOI Creative Commons
Beate Mayer, Pavel Babál, Lucia Krivošíková

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2025, Volume and Issue: 21(1)

Published: Jan. 21, 2025

Considering the increasing use of immune checkpoint inhibitors in cancer treatment, our aim is to report a rare cutaneous immune-related adverse event induced by PD-1 inhibitor pembrolizumab and provide brief overview pembrolizumab-induced subacute lupus erythematosus (SCLE) cases literature. We 67-year-old woman with oropharyngeal squamous cell carcinoma who developed SCLE during treatment pembrolizumab. After 18 weeks (sixth cycle) immunotherapy, widespread pruritic erythematous rash evaluated as grade 3 appeared primarily on patient's limbs. Histopathological examination direct immunofluorescence showed characteristic features SCLE. The patient was treated oral prednisone 40 mg daily topical corticosteroids. In 2 weeks, her had cleared up significantly pruritus disappeared. an infrequent but recognized linked treatment.

Language: Английский

Citations

1
Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients DOI Creative Commons

Ting Yan,

Minghui Long,

Chaoyi Liu

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: Jan. 31, 2025

Immune checkpoint inhibitors (ICIs) have significantly changed cancer therapy, improving patient survival rates and clinical outcomes. Nevertheless, the use of PD-1/PD-L1 can result in immune-related adverse events (irAEs). This study aims to investigate prevalence associated risk factors irAEs a real-world setting, as well assess their effects on optimal therapeutic A retrospective analysis involved 2523 patients with who received inpatient treatment between January 2018 December 2022. We documented patients' demographic characteristics, PD-1 or PD-L1 inhibitors, modalities, incidences, timing, severity irAEs, efficacy outcomes by reviewing records. Patients were categorized into an group non-irAEs group, former further subdivided multiple single irAE group. Chi-square tests employed evaluate differences baseline characteristics groups, groups. Additionally, logistic regression was utilized identify linked irAEs. Among eligible patients, 1096 reported 1802 incidence 43.4%. individuals, 92.1% classified grade 1-2, while 7.9% 3 higher. IrAEs affected various organ systems, endocrine toxicity (17.7%), hepatic (17.2%), hematologic (11.4%) being most common. 20.5% experienced multi-system The average time for develop within four cycles. Significant gender, age, Eastern Cooperative Oncology Group (ECOG) Performance Status (PS), comorbidities, modalities observed but not Compared exhibited higher objective response rate (ORR) disease control (DCR), also showed ORR than indicated that occurrence is related ECOG PS, modalities. may be better benefits.

Language: Английский

Citations

1
Microbiome Integrity Enhances the Efficacy and Safety of Anticancer Drug DOI Creative Commons
Alice Njolke Mafe, Dietrich Büsselberg

Biomedicines, Journal Year: 2025, Volume and Issue: 13(2), P. 422 - 422

Published: Feb. 10, 2025

The intricate relationship between anticancer drugs and the gut microbiome influences cancer treatment outcomes. This review paper focuses on role of integrity in enhancing efficacy safety drug therapy, emphasizing pharmacokinetic interactions microbiota. It explores how disruptions to composition, or dysbiosis, can alter metabolism, immune responses, side effects. By examining mechanisms disruption caused by drugs, this highlights specific case studies like cyclophosphamide, 5-fluorouracil, irinotecan, their impact microbial diversity clinical also discusses microbiome-targeted strategies, including prebiotics, probiotics, postbiotics, fecal microbiota transplantation (FMT), as promising interventions enhance treatment. Furthermore, potential profiling personalizing therapy integrating these into practice is explored. Finally, proposes future research directions, developing novel biomarkers a deeper comprehension drug-microbiome interactions, respond current gaps knowledge improve patient outcomes care.

Language: Английский

Citations

1